Amgen (AMGN) Non Operating Income (2009 - 2026)
Amgen (AMGN) posted quarterly Non Operating Income of $75.0 million for Q1 2026, down 95.06% year-over-year from $1.5 billion in Q1 2025, and up 113.56% quarter-over-quarter from -$553.0 million in Q4 2025.
Amgen (AMGN) Non Operating Income (2009 - 2026) Analysis & Trends
Amgen's Non Operating Income history runs 18 years deep, the most recent figure standing at $75.0 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 95.06% year-over-year to $75.0 million; the TTM figure through Mar 2026 stood at $1.2 billion (down 46.53% YoY), while the FY2025 annual figure was $2.7 billion, up 423.91% from the prior year.
- Non Operating Income for Q1 2026 stood at $75.0 million, up from -$553.0 million in the prior quarter.
- The five-year high for Non Operating Income was $2.1 billion in Q3 2025, with the low at -$782.0 million in Q4 2024.
- The 5-year median for Non Operating Income is -$67.0 million (2022), against an average of $308.9 million.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income plunged 4176.92% in 2022, then jumped 745.96% in 2025.
- Amgen's Non Operating Income stood at -$67.0 million in 2022, then jumped by 700.0% to $402.0 million in 2023, then plunged by 294.53% to -$782.0 million in 2024, then increased by 29.28% to -$553.0 million in 2025, then soared by 113.56% to $75.0 million in 2026.
- Business Quant data shows AMGN's Non Operating Income at $75.0 million in Q1 2026, -$553.0 million in Q4 2025, and $2.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -73.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 387.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -73.00 Mn |
| Mar 31, 2026 | 75.00 Mn |
| Dec 31, 2025 | -553.00 Mn |
| Sep 30, 2025 | 2.08 Bn |
| Jun 30, 2025 | -394.00 Mn |
| Mar 31, 2025 | 1.52 Bn |
| Dec 31, 2024 | -782.00 Mn |
| Sep 30, 2024 | 1.83 Bn |
| Jun 30, 2024 | -307.00 Mn |
| Mar 31, 2024 | -235.00 Mn |
| Dec 31, 2023 | 402.00 Mn |
| Sep 30, 2023 | 685.00 Mn |
| Jun 30, 2023 | -318.00 Mn |
| Mar 31, 2023 | 2.06 Bn |
| Dec 31, 2022 | -67.00 Mn |
| Sep 30, 2022 | 100.00 Mn |
| Jun 30, 2022 | -317.00 Mn |
| Mar 31, 2022 | -530.00 Mn |
| Dec 31, 2021 | 162.00 Mn |
| Sep 30, 2021 | 73.00 Mn |